
Thoracic Surgeon @Northwellhealth SIUH. Father to two sons. MD Downstate. Gen Surg NYP-Q. Thoracic BWH. CT Montefiore.
Bronx, NY
Joined March 2018
- Tweets798
- Following631
- Followers339
- Likes4.5K
Roger Zhu, MD retweeted
The best set of slides on the potential impact of neoadjuvant chemo/immunotherapy ever by @nchudgar ?
But putting our great surgeons out of business? Not yet pls- we love them on our multi-D team!
Maybe we can find a new role for them when resections no longer needed? 😉
@BrendonStilesMD @NitinOhri3
Roger Zhu, MD retweeted
📦🚨 PSA 10 Mega Gengar ex/PSA 10 Mega Charizard X ex Mystery Box Giveaway! 📦🚨
To enter:
✅ Repost and Like this Tweet
✅ Follow @PokeTCGAlerts and @DannypTCG
Optional: Tag a friend and comment what you hope to get!
This giveaway is for 1 FREE Mystery Box. Top chases include PSA 10 Mega Gengar ex and PSA 10 Mega Charizard X ex.
Winner will be picked this Tuesday, June 9th! US only. Good luck!
If you don't win you can buy a Mystery Box from Danny! Only 120 Mystery Boxes available. Boxes go live this Tuesday, June 9th at 5pm PST
If you want to buy a Mystery box make sure to follow @DannypTCG and turn on notifications.
Full details below 👇
Roger Zhu, MD retweeted
Proud to see this out from @ElsevierNews! Incredible contributions from many leaders in the field. Surgeons need to know systemic therapy! @BalazsHalmosMD
@IsaOpitz @LindaMThoracic @GavittWoodard @DoctorJSpicer Jay Lee Masahiro Tsuboi @JonesDavid2013 @NitinOhri3 @maraantonoff
Roger Zhu, MD retweeted
Happy New Year Oncology Twitter! 🥳
Reminder: first round of travel award applications due in 10 days.
Roger Zhu, MD retweeted
I would encourage all my colleagues confused by the 10 year follow up results from JCOG 0802 to watch this interview with Nasser Altorki @AltorkiNasser
ctsnet.org/article/10-year-j…
Here is a brief clip that I think summarizes the bottom line nicely
I feel compelled to circle back to this "bombshell" revelation posted on CTSNET. I don't intend to criticize my surgical colleagues, but I fail to understand the rationale for this webinar or how they reached the supposed "bombshell" conclusions...
ctsnet.org/article/bombshell…
Roger Zhu, MD retweeted
teapaw.org/changjeesuk1/status/20…
I had been trying to quietly disengage from this conversation (I promise!), but this pulled back in. Respectfully, I would suggest that not operating on biopsy proven NSCLC after SBRT should not be promoted as SOC. Several points important to make here:
Roger Zhu, MD retweeted
The outcomes with non-surgical treatment for stage III NSCLC pioneered by a Spanish group reported in Nature Communications. @_ShankarSiva @fcounago @SalmaJabbour1 @NitinOhri3
nature.com/articles/s41467-0…
PFS was 68.4% (95% CI, 51.1–80.7) at 12 months (*statistically significant* compared to null hypothesis of 55%)
GECP SpanishLung Cáncer Group, Do it again for Christmas.
Roger Zhu, MD retweeted
I feel compelled to circle back to this "bombshell" revelation posted on CTSNET. I don't intend to criticize my surgical colleagues, but I fail to understand the rationale for this webinar or how they reached the supposed "bombshell" conclusions...
ctsnet.org/article/bombshell…
Roger Zhu, MD retweeted
"Bombshell" may be a stretch, but interesting to ponder long term results of JCOG0802. No meaningful differences between segmentectomy & lobectomy. Choice may ultimately come down to individual patient risk factors, tumor characteristics, & preferences.
ctsnet.org/article/bombshell…
Roger Zhu, MD retweeted
Outstanding opportunity to attend one of the best meetings in thoracic oncology!
Submit your abstract now for the #TexasLung26 Poster Competition! Open to trainees & junior faculty. Winners receive registration, travel, & hotel to present their poster at the meeting - Austin City Limits, April 9-11, 2026. See you @TLCconference!
thetlcconference.com/poster-…
Roger Zhu, MD retweeted
Lung metastases
Excellent review👇
nature.com/articles/s41572-0…
Roger Zhu, MD retweeted
This could be the next new quality metric having timely surgery for early stage lung cancer improves survival - @AATSHQ @AATSED @STS_CTsurgery @AmColSurgCancer @AmCollSurgeons @NLCRTnews @accpchest @GO2forLungCancr @atstoa @StanfordCAREs @KPDOR @KPMedSchool
A study by KPSOM faculty members, Drs. Lori Sakoda and Jeffrey Velotta, underscores the need for timely intervention in early-stage lung cancer. Read more: kpsom.link/40Nxh70
Roger Zhu, MD retweeted
🚨 HOW TO DRIVE A LAPAROSCOPIC CAMERA 🚨
From DOMINATE SURGERY for medical students ➡️ app.behindtheknife.org/cours…
Roger Zhu, MD retweeted
In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN phase 3 trial results and Research Summary: nej.md/437IXTF

ALT The New England Journal of Medicine Perioperative Durvalumab in Gastric Cancer A Research Summary based on Janjigian YY et al. | 10.1056/NEJMoa2503701 | Published on June 1, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
Roger Zhu, MD retweeted
Perhaps a new upcoming quality metric? Surgeries > 8 weeks from suspicious CT SCAN for early stage NSCLC had worse survival!!!! @AATSHQ @AATSED @STS_CTsurgery @AmCollSurgeons @KPDOR @KPMedSchool @UCSFSurgery
Free for 30 days: Time to surgery in early-stage non–small cell lung cancer: Defining the optimal diagnosis-to-resection interval to reduce mortality. Read in #JTCVS while it's open for all: doi.org/10.1016/j.jtcvs.2024…
@JVelottaMD @KPDOR
Roger Zhu, MD retweeted
Congrats on terrific presentation for Dr. Chaft @ChaftJamie on the 3-arm NEOADAURA trial showing much improved MPR/nodal downstaging by neoadj osi and chemo/osi vs chemo alone (which is pitiful on its own btw..) and excellent EFS for pts achieving MPR
We will be scratching our heads a little as to how we will integrate this into practice but neoadj Ohhh-simertinib +/- chemo does have an appeal for N+/borderline resectable patients for sure!
#ASCO25
Roger Zhu, MD retweeted
~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In @NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! nejm.org/doi/full/10.1056/NE… #LCSM 1/
Roger Zhu, MD retweeted
Lots to think about!
-If OS in CM816 shows similar improvement to KN671, should it be preferred regimen?
-Will data dispel perceived need for adjuvant ICI after pCR?
-Will neoadj TKIs move the needle?
-Shouldn't we double down on increasing systemic therapy induced pCR?
#ASCO25
Replying to @hari_keshava @PatelOncology @NarjustFlorezMD @MNagasaka @DrewMoghanaki @BrendonStilesMD @StephenVLiu @LindaMThoracic @FordePatrick
I recommend checking out the CM816 OS, the outcomes by molecular profile from 77T, the first report of NeoADAURA findings and the complete data on arms 1, 2 and 4 of NeoCOAST2! Lots of great data that will inform practice and the next generation of phase 3 trials!
Roger Zhu, MD retweeted
Retrospective study of neoadjuvant immunotherapy for 112 pts with stage III borderline resectable NSCLC @JAMAOnc. Included stage III with T4 and/or N2/3 NSCLC and 75% underwent surgery with 29% pCR, 42.2% MPR, mEFS 52.6m. Impressive to note that all N3 achieved ypN0.
Roger Zhu, MD retweeted
This morning Dr. Goldstein received the @ISHLT 2025 Francis D. Pagani Endowed Mentorship Award for his tireless effort and commitment to mentoring the next generation of heart failure surgeons. 👏 #ISHLT2025














































